



JFW

PATENT
Docket No. 249.0007 0101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Dominic COSGROVE) Group Art Unit: 1614
Serial No.: 10/698,121)
Confirmation No.: 8958)
Filed: 31 October 2003)
For: INDUCIBLE LIGAND FOR α 1 β 1 INTEGRIN AND USES


INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with C.F.R. §§ 1.97 *et. seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Per M.P.E.P. § 609, the information cited in the present Information Disclosure Statement shall not be construed to be an admission that the information is, or is considered to be, material to patentability. Consideration of each of the documents listed on the attached 1449 form(s) is respectfully requested. As this patent application was filed after June 30, 2003, copies of the U.S. patents and U.S. patent application publications listed on the attached 1449 form(s) have not been submitted. Pursuant to the provisions of M.P.E.P. § 609, Applicant further requests that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

It is believed that no fee is due, as this Information Disclosure Statement is filed prior to the receipt of any Action on the merits. However, in the event a fee is due, please charge any fee or credit any overpayment to Account No. 13-4895.



INFORMATION DISCLOSURE STATEMENT

Page 2

Applicant(s): Dominic COSGROVE
Serial No.: 10/698,121
Filed: 31 October 2003
For: INDUCIBLE LIGAND FOR $\alpha 1 \beta 1$ INTEGRIN AND USES

The Examiner is invited to contact Applicant's Representatives at the below-listed telephone number, if they can be of any assistance during prosecution of the present application.

CERTIFICATE UNDER 37 C.F.R. 1.8:

The undersigned hereby certifies that this paper is being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 19 day of AUGUST, 2004.

Signature: *[Signature]*

Printed Name: *[Signature]*

Respectfully submitted for

Dominic COSGROVE,

By

Mueting, Raasch & Gebhardt, P.A.

P.O. Box 581415

Minneapolis, MN 55458-1415

Phone: (612)305-1220

Facsimile: (612)305-1228

Customer Number 26813

August 19, 2004
Date

By: *[Signature]*
Ann M. Mueting
Reg. No. 33,977
Direct Dial (612)305-1217



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Dominic COSGROVE Group Art Unit: 1614
Serial No.: 10/698,121 Examiner: Unknown
Filed: 31 October 2003 Docket No.: 249.0007 0101
Confirmation No.: 8958
Title: INDUCIBLE LIGAND FOR $\alpha 1 \beta 1$ INTEGRIN AND USES

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

We are transmitting the following documents along with this Transmittal Sheet (which is submitted in triplicate):


- ☒ Small entity status is entitled to be asserted in the above-identified application.
☒ An itemized return postcard.
— A Petition for Extension of Time for __ month(s) and a check in the amount of \$__ for the required fee.
☒ An Information Disclosure Statement (2 pgs); copies of 0 applications; 1449 forms (3 pgs); and copies of 27 documents cited on the 1449 forms.
— A check in the amount of \$__, representing ____.
— A certified copy of a __ application, Serial No. __, filed _____, the right of priority of which is claimed under 35 U.S.C. §119.
— Other: ____.
— Amendment ☐ No Additional fee is required. ☐ The fee has been calculated as shown:

Fee Calculation for Claims Pending After Amendment					
	Pending Claims after Amendment (1)	Claims Paid for Earlier (2)	Number of Additional Claims (1-2)	Cost per Additional Claim	Additional Fees Required
Total Claims				x \$9 =	
Independent Claims				x \$43 =	
One or More New Multiple Dependent Claims Presented? If Yes, Add \$145 Here →					
Total Additional Claim Fees Required					\$0


Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895. Triplicate copies of this sheet are enclosed.

CERTIFICATE UNDER 37 C.F.R. §1.8: The undersigned hereby certifies that this Transmittal Letter and the paper(s), as described hereinabove, are being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 19 day of August, 2004.

MUETING, RAASCH & GEBHARDT, P.A.
Customer Number: 26813

By: 
Name: Ann M. Mueeting
Reg. No.: 33,977
Direct Dial: 612-305-1217
Facsimile: 612-305-1228

(SMALL ENTITY TRANSMITTAL UNDER RULE 1.8)



INFORMATION DISCLOSURE STATEMENT	Atty. Docket No.: 249.0007 0101	Serial No.: 10/698,121
	Applicant(s): Dominic COSGROVE	Confirmation No.: 8958
	Application Filing Date: 31 October 2003	Group: 1614
	Information Disclosure Statement mailed: <u>19</u> August 2004	

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
		none					

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
		none						

OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)

Examiner Initial		Document Description
		Adams et al., "Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence", <i>Nature</i> , 377(6547 Suppl.):3-174 (28 September 1995).
		Andreasen et al., "Expression and Functional Importance of Collagen-Binding Integrins, $\alpha_1\beta_1$ and $\alpha_2\beta_1$, on Virus-Activated T Cells ¹ ", <i>The Journal of Immunology</i> , 2003, pgs. 2804-2811.
		Bank et al., "Lymphocytes Expressing $\alpha_1\beta_1$ Integrin (Very Late Antigen-1) in Peripheral Blood of Patients with Arthritis Are a Subset of CD45RO ⁺ T-Cells Primed for Rapid Adhesion to Collagen IV", <i>Clinical Immunology</i> , 105(3):247-258 (December 2002).
		Border et al., "Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β_1 ", <i>Nature</i> , 346:371-374 (26 July 1990).
		Conti et al., "MCP-1 and RANTES Are Mediators of Acute and Chronic Inflammation", <i>Allergy and Asthma Proc.</i> , 22:133-137 (May-June 2001).
		Cook et al., "Treatment with an Antibody to VLA-1 Integrin Reduces Glomerular and Tubulointerstitial Scarring in a Rat Model of Crescentic Glomerulonephritis", <i>American Journal of Pathology</i> , 161(4):1265-2172 (04 October 2002).

EXAMINER	Date Considered
<small>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	

INFORMATION DISCLOSURE STATEMENT	Atty. Docket No.: 249.0007 0101	Serial No.: 10/698,121
	Applicant(s): Dominic COSGROVE	Confirmation No.: 8958
	Application Filing Date: 31 October 2003	Group: 1614
	Information Disclosure Statement mailed: <u>19</u> August 2004	

Examiner Initial	Document Description
	Cosgrove et al., "Integrin $\alpha 1\beta 1$ and Transforming Growth Factor- $\beta 1$ Play Distinct Roles in Alport Glomerular Pathogenesis and Serve as Dual Targets for Metabolic Therapy", <i>American Journal of Pathology</i> , 157(5):1649-1659 (November 2000).
	De Fougerolles et al., "Regulation of inflammation by collagen-binding integrins $\alpha 1\beta 1$ and $\alpha 2\beta 1$ in models of hypersensitivity and arthritis", <i>The Journal of Clinical Investigation</i> , 105(6):721-729 (March 2000).
	Gardner et al., "Deletion of Integrin $\alpha 1$ by Homologous Recombination Permits Normal Murine Development but Gives Rise to a Specific Deficit in Cell Adhesion", <i>Developmental Biology</i> , 175:301-312 (1996).
	Gowen et al., "The collagenous domain of class A scavenger receptors is involved in macrophage adhesion to collagens", <i>Journal of Leukocyte Biology</i> , 69:575-582 (April 2001).
	Hägg et al., "Type XIII Collagen: a novel cell adhesion component present in a range of cell-matrix adhesions and in the intercalated discs between cardiac muscle cells", <i>Matrix Biology</i> , 19:727-742 (2001).
	Hägg et al., "Type XIII Collagen is Identified as a Plasma Membrane Protein", <i>The Journal of Biological Chemistry</i> , 273(25):15590-15597 (19 June 1998).
	Harlan et al., "Leukocyte-endothelial interactions: Clinical trials of anti-adhesion therapy", <i>Crit Care Med</i> , 30(5(Suppl.)):S214-S219 (2002).
	Heeringa et al, "Renal expression of endothelial and inducible nitric oxide synthase, and formation of peroxynitrite-modified proteins and reactive oxygen species in Wegener's granulomatosis", <i>Journal of Pathology</i> , 193:224-232 (2001).
	Kim et al., "Cytokines and adhesion molecules in stroke and related diseases", <i>Journal of the Neurological Sciences</i> , 137:69-78 (1996).
	Kosswig et al., "Class A Scavenger Receptor-mediated Adhesion and Internalization Require Distinct Cytoplasmic Domains", <i>The Journal of Biological Chemistry</i> , 278(36):34219-34225 (05 September 2003).
	Krieglstein et al., "Collagen-binding integrin $\alpha 1\beta 1$ regulates intestinal inflammation in experimental colitis", <i>The Journal of Clinical Investigation</i> , 110(12):1773-1782 (December 2002).

EXAMINER	Date Considered
<p>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

INFORMATION DISCLOSURE STATEMENT	Atty. Docket No.: 249.0007 0101	Serial No.: 10/698,121
	Applicant(s): Dominic COSGROVE	Confirmation No.: 8958
	Application Filing Date: 31 October 2003	Group: 1614
	Information Disclosure Statement mailed: <u>19</u> August 2004	

Examiner Initial	Document Description
	Kvist et al., "Animal Model. Lack of Cytosolic and Transmembrane Domains of Type XIII Collagen Results in Progressive Myopathy", <i>American Journal of Pathology</i> , 159(4):1581-1593 (04 October 2001).
	Lalor et al., "Vascular Adhesion Protein-1 Mediates Adhesion and Transmigration of Lymphocytes on Human Hepatic Endothelial Cells", <i>The Journal of Immunology</i> , 169:983-992 (2002).
	Luby-Phelps, "Preparation of Fluorescently Labeled Dextrans and Ficolls", <i>Methods in Cell Biology</i> , 29:Chapter 4, pgs. 59-73 (1989).
	Nykqvist et al., "Distinct Recognition of Collagen Subtypes by $\alpha_1\beta_1$ and $\alpha_2\beta_1$ Integrins", <i>The Journal of Biological Chemistry</i> , 275(11):8255-8261 (17 March 2000).
	Rodgers et al., "Monocytes may promote myofibroblast accumulation and apoptosis in Alport renal fibrosis", <i>Kidney International</i> , 63:1338-1355 (2003).
	Roebuck, "Oxidant stress regulation of IL-8 and ICAM-1 gene expression: Differential activation and binding of the transcription factors AP-1 and NF- κ B (Review)", <i>International Journal of Molecular Medicine</i> , 4:223-230 (1999).
	Ruoslahti, "Targeting tumor vasculature with homing peptides from phage display", <i>seminars in CANCER BIOLOGY</i> , 10:435-442 (2000).
	Sampson et al., "Global Gene Expression Analysis Reveals a Role for the α_1 Integrin in Renal Pathogenesis", <i>The Journal of Biological Chemistry</i> , 276(36):34182-34188 (07 September 2001).
	Yoon et al., "Sustained Production of H ₂ O ₂ Activates Pro-matrix Metalloproteinase-2 through Receptor Tyrosine Kinases/Phosphatidylinositol 3-Kinase/NF- κ B Pathway", <i>The Journal of Biological Chemistry</i> , 277(33):30271-30282 (16 August 2002).
	Yusuf-Makagiansar et al., "Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a Therapeutic Approach to Inflammation and Autoimmune Diseases", <i>Medicinal Research Reviews</i> , 22(2):146-167 (2002).

EXAMINER	Date Considered
<p>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	